Importantly, we show that targeting one of these factors, Spi1, by direct administration of novel pharmacological agents allows us to delineate whether these modules are drivers or consequences of disease, and our data highlight the potential for targeting increased Spi1 responses in the lungs as a novel therapeutic strategy to reduce remodeling and AHR in asthma patients. The gene discussed is SPI1; the disease is asthma.